Differentiated Thyroid Carcinoma Clinical Trial
Official title:
A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy
ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00251316 -
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT01704586 -
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer
|
N/A | |
| Completed |
NCT03776123 -
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
|
||
| Recruiting |
NCT03167385 -
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04916262 -
Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer
|
||
| Active, not recruiting |
NCT04970134 -
Spanish Study for Molecular Characterization of Thyroid Carcinoma
|
||
| Completed |
NCT00439127 -
OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation
|
N/A | |
| Recruiting |
NCT03845647 -
Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.
|
N/A |